Momenta is a biotechnology company with a product pipeline of generic and novel drugs. The company’s drug candidate M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox, a low molecular weight heparin used to prevent and treat deep vein thrombosis and to support the treatment of acute coronary syndromes. Its second major generic product candidate is M356, a technology-enabled generic version of Copaxone a drug that is indicated for the reduction of the frequency of relapses in patients with Relapse-Remitting Multiple Sclerosis. The company’s lead novel drug candidate, M118, has been engineered to to support the treatment of ACS.
CSRHub includes data on Sustainability, climate change solutions, CSR ratings, Chief Executives for Corporate Purpose, Employees, and real estate investing.